CNBC's Huckman On JAMA/Plavix Study

Tuesday, 5 Dec 2006 | 5:07 PM ET

Bristol-Myers got some good news Tuesday afternoon-- and CNBC's Mike Huckman had the story. A new report from the Journal of the American Medical Association says long term use of Plavix--reduces significant health risks.

The JAMA report says that if patients stay on Plavix for two years--the drug will greatly reduce or eliminate heart attacks. The FDA say patients with drug coated implanted stents should take Plavix for up to 6 months after certain stents are implanted.

Plavix is the largest selling biggest pharmaceutical drug for Bristol-Meyers. It's a blood thinner. It has seen some sales declines recently due to a generic competitors.

Plavix Update
A major new study shows that drug-coated stents and Plavix may reduce and even eliminate the risk of death from a heart attack, with Mike Huckman, CNBC Business News Pharmaceutical Reporter
  Price   Change %Change



  • Showtimes

    United States
    Monday - Friday 3:00P ET
    Monday - Saturday 21:00 CET
    Tuesday - Saturday 03:00 SIN/HK
    Tuesday - Saturday 05:00 SYD
    New Zealand
    Tuesday - Saturday 07:00 NZ
  • With almost 30 years experience in business television, Bill Griffeth is co-anchor of the 3 p.m. ET hour of CNBC's "Closing Bell."

  • Kelly Evans

    Kelly Evans is an on-air correspondent, reporting across CNBC's business day programming. She is co-anchor of CNBC's "Squawk on the Street."